| Circulating ghrelin levels are decreased in human obesity M Tschop, C Weyer, PA Tataranni, V Devanarayan, E Ravussin, ... Diabetes 50 (4), 707-709, 2001 | 2723 | 2001 |
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models Nature biotechnology 28 (8), 827-838, 2010 | 849 | 2010 |
| Fit-for-purpose method development and validation for successful biomarker measurement JW Lee, V Devanarayan, YC Barrett, R Weiner, J Allinson, S Fountain, ... Pharmaceutical research 23, 312-328, 2006 | 849 | 2006 |
| A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium Nature biotechnology 32 (9), 903-914, 2014 | 842 | 2014 |
| Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products AR Mire-Sluis, YC Barrett, V Devanarayan, E Koren, H Liu, M Maia, ... Journal of immunological methods 289 (1-2), 1-16, 2004 | 673 | 2004 |
| Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products G Shankar, V Devanarayan, L Amaravadi, YC Barrett, R Bowsher, ... Journal of pharmaceutical and biomedical analysis 48 (5), 1267-1281, 2008 | 596 | 2008 |
| The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance C Wang, B Gong, PR Bushel, J Thierry-Mieg, D Thierry-Mieg, J Xu, ... Nature biotechnology 32 (9), 926-932, 2014 | 511 | 2014 |
| Comparison of RNA-seq and microarray-based models for clinical endpoint prediction W Zhang, Y Yu, F Hertwig, J Thierry-Mieg, W Zhang, D Thierry-Mieg, ... Genome biology 16, 1-12, 2015 | 395 | 2015 |
| Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products E Koren, HW Smith, E Shores, G Shankar, D Finco-Kent, B Rup, ... Journal of Immunological Methods 333 (1-2), 1-9, 2008 | 341 | 2008 |
| Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations G Shankar, S Arkin, L Cocea, V Devanarayan, S Kirshner, A Kromminga, ... The AAPS journal 16, 658-673, 2014 | 280 | 2014 |
| Ritonavir and saquinavir combination therapy for the treatment of HIV infection W Cameron, AJ Japour, Y Xu, A Hsu, J Mellors, C Farthing, C Cohen, ... Aids 13 (2), 213-224, 1999 | 254 | 1999 |
| Reporting guidelines for human microbiome research: the STORMS checklist C Mirzayi, A Renson, Genomic Standards Consortium, ... Nature medicine 27 (11), 1885-1892, 2021 | 196 | 2021 |
| Immunoassay methods KL Cox, V Devanarayan, A Kriauciunas, J Manetta, C Montrose, ... Assay Guidance Manual [Internet], 2019 | 190 | 2019 |
| HTS assay validation PW Iversen, B Beck, YF Chen, W Dere, V Devanarayan, BJ Eastwood, ... Assay guidance manual [internet], 2012 | 180 | 2012 |
| Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum CA Ray, RR Bowsher, WC Smith, V Devanarayan, MB Willey, JT Brandt, ... Journal of pharmaceutical and biomedical analysis 36 (5), 1037-1044, 2005 | 163 | 2005 |
| Confirmatory reanalysis of incurred bioanalytical samples ML Rocci, V Devanarayan, DB Haughey, P Jardieu The AAPS journal 9, E336-E343, 2007 | 162 | 2007 |
| Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics S Gupta, V Devanarayan, D Finco, GR Gunn III, S Kirshner, S Richards, ... Journal of pharmaceutical and biomedical analysis 55 (5), 878-888, 2011 | 137 | 2011 |
| First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates S Sankaranarayanan, MA Holahan, D Colussi, MC Crouthamel, ... Journal of Pharmacology and Experimental Therapeutics 328 (1), 131-140, 2009 | 129 | 2009 |
| Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells J Sampath, PR Long, RL Shepard, X Xia, V Devanarayan, GE Sandusky, ... The American journal of pathology 163 (5), 1781-1790, 2003 | 89 | 2003 |
| Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines SK Tahir, J Wass, MK Joseph, V Devanarayan, P Hessler, H Zhang, ... Molecular cancer therapeutics 9 (3), 545-557, 2010 | 85 | 2010 |
Ronald R. Bowsher, Ph.D.B2S Life SciencesDirección de correo verificada de B2SLifeSciences.com
